The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir alafenamide in Treatment Experienced Patients

Authors

Ciara Walshe, PharmD Candidate, Thomas Jefferson UniversityFollow
Jason J. Schafer, PharmD, MPH, BCPS-AQ ID, BCIDP, AAHIVP, Thomas Jefferson UniversityFollow

Files

Description

Objective

• The primary outcome was to measure the proportion of patients experiencing DIs before and after the ART switch.
• The secondary outcome was to measure changes in DI scores before and after the ART switch.

Publication Date

3-21-2020

Keywords

HIV, antiretroviral, drug interactions, bictegravir

Disciplines

Medicine and Health Sciences | Pharmacy and Pharmaceutical Sciences

Comments

Presented at the 2020 American Pharmacists Association (APhA) Annual Meeting & Exposition

Recommended Citation

Walshe, PharmD Candidate, Ciara and Schafer, PharmD, MPH, BCPS-AQ ID, BCIDP, AAHIVP, Jason J., "The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir alafenamide in Treatment Experienced Patients" (2020). College of Pharmacy Posters. 21.
https://jdc.jefferson.edu/pharmacyposters/21